Provider: Nature Publishing Group Content: application/x-research-info-systems TY - JOUR AU - Johnson, J. I. TI - Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials JA - Br. J. Cancer PY - 2001/// VL - 84 SP - 1424 EP - 1431 M3 - 10.1054/bjoc.2001.1796 N1 - 10.1054/bjoc.2001.1796 UR - http://dx.doi.org/10.1054/bjoc.2001.1796 ER - TY - JOUR AU - Voskoglou-Nomikos, T. AU - Pater, J. L. AU - Seymour, L. TI - Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models JA - Clin. Cancer Res. PY - 2003/// VL - 9 SP - 4227 EP - 4239 ER - TY - JOUR AU - Stehelen, D. AU - Varmus, H. E. AU - Bishop, J. M. AU - Vogt, P. K. TI - DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA JA - Nature PY - 1976/// VL - 260 SP - 170 EP - 173 M3 - 10.1038/260170a0 N1 - 10.1038/260170a0 UR - http://dx.doi.org/10.1038/260170a0 ER - TY - JOUR AU - Brugge, J. S. AU - Erikson, R. L. TI - Identification of a transformation-specific antigen induced by an avian sarcoma virus JA - Nature PY - 1977/// VL - 269 SP - 346 EP - 348 M3 - 10.1038/269346a0 N1 - 10.1038/269346a0 UR - http://dx.doi.org/10.1038/269346a0 ER - TY - JOUR AU - Collett, M. S. AU - Erikson, R. L. TI - Protein kinase activity associated with the avian sarcoma virus src gene product JA - Proc. Natl Acad. Sci. USA PY - 1978/// VL - 75 SP - 2021 EP - 2024 ER - TY - JOUR AU - Levinson, A. D. AU - Oppermann, H. AU - Varmus, H. E. AU - Bishop, J. M. TI - Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein JA - Cell PY - 1978/// VL - 15 SP - 561 EP - 572 M3 - 10.1016/0092-8674(78)90024-7 N1 - 10.1016/0092-8674(78)90024-7 UR - http://dx.doi.org/10.1016/0092-8674(78)90024-7 ER - TY - JOUR AU - Blume-Jensen, P. AU - Hunter, T. TI - Oncogenic kinase signalling JA - Nature PY - 2001/// VL - 411 SP - 355 EP - 365 M3 - 10.1038/35077225 N1 - 10.1038/35077225 UR - http://dx.doi.org/10.1038/35077225 ER - TY - JOUR AU - Baselga, J. AU - Arteaga, C. L. TI - Critical update and emerging trends in epidermal growth factor receptor targeting in cancer JA - J. Clin. Oncol. PY - 2005/// VL - 23 SP - 2445 EP - 2459 M3 - 10.1200/JCO.2005.11.890 N1 - 10.1200/JCO.2005.11.890 UR - http://dx.doi.org/10.1200/JCO.2005.11.890 ER - TY - JOUR AU - Jain, R. K. AU - Duda, D. G. AU - Clark, J. W. AU - Loeffler, J. S. TI - Lessons from phase III clinical trials on anti-VEGF therapy for cancer JA - Nature Clin. Pract. Oncol. PY - 2006/// VL - 3 SP - 24 EP - 40 ER - TY - JOUR AU - Gum, R. J. TI - Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket JA - J. Biol. Chem. PY - 1998/// VL - 273 SP - 15605 EP - 15610 M3 - 10.1074/jbc.273.25.15605 N1 - 10.1074/jbc.273.25.15605 UR - http://dx.doi.org/10.1074/jbc.273.25.15605 ER - TY - JOUR AU - Wang, Z. TI - Structural basis of inhibitor selectivity in MAP kinases JA - Structure PY - 1998/// VL - 6 SP - 1117 EP - 1128 M3 - 10.1016/S0969-2126(98)00113-0 N1 - 10.1016/S0969-2126(98)00113-0 UR - http://dx.doi.org/10.1016/S0969-2126(98)00113-0 ER - TY - JOUR AU - Kostich, M. TI - Human members of the eukaryotic protein kinase family JA - Genome Biol. PY - 2002/// VL - 3 ER - TY - JOUR AU - Manning, G. AU - Whyte, D. B. AU - Martinez, R. AU - Hunter, T. AU - Sudarsanam, S. TI - The protein kinase complement of the human genome JA - Science PY - 2002/// VL - 298 SP - 1912 EP - 1934 M3 - 10.1126/science.1075762 N1 - 10.1126/science.1075762 UR - http://dx.doi.org/10.1126/science.1075762 ER - TY - JOUR AU - Dudley, D. T AU - Pang, L. AU - Decker, S. J. AU - Bridges, A. J. AU - Saltiel, A. R. TI - A synthetic inhibitor of the mitogen-activated protein kinase cascade JA - Proc. Natl Acad. Sci. USA PY - 1995/// VL - 92 SP - 7686 EP - 7689 ER - TY - JOUR AU - Favata, M. F. TI - Identification of a novel inhibitor of mitogen-activated protein kinase kinase JA - J. Biol. Chem. PY - 1998/// VL - 273 SP - 18623 EP - 18632 M3 - 10.1074/jbc.273.29.18623 N1 - 10.1074/jbc.273.29.18623 UR - http://dx.doi.org/10.1074/jbc.273.29.18623 ER - TY - JOUR AU - Bain, J. AU - McLauchlan, H. AU - Elliott, M. AU - Cohen, P. TI - The specificities of protein kinase inhibitors: an update JA - Biochem. J. PY - 2003/// VL - 371 SP - 199 EP - 204 M3 - 10.1042/BJ20021535 N1 - 10.1042/BJ20021535 UR - http://dx.doi.org/10.1042/BJ20021535 ER - TY - JOUR AU - Ohren, J. TI - Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition JA - Nature Struct. Biol. PY - 2004/// VL - 11 SP - 1192 EP - 1197 M3 - 10.1038/nsmb859 N1 - 10.1038/nsmb859 UR - http://dx.doi.org/10.1038/nsmb859 ER - TY - JOUR AU - Schindler, T. TI - Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase JA - Science PY - 2000/// VL - 289 SP - 1938 EP - 1942 M3 - 10.1126/science.289.5486.1938 N1 - 10.1126/science.289.5486.1938 UR - http://dx.doi.org/10.1126/science.289.5486.1938 ER - TY - JOUR AU - Pargellis, C. TI - Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site JA - Nature Struct. Biol. PY - 2002/// VL - 9 SP - 268 EP - 272 M3 - 10.1038/nsb770 N1 - 10.1038/nsb770 UR - http://dx.doi.org/10.1038/nsb770 ER - TY - JOUR AU - Wan, C. TI - Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF JA - Cell PY - 2004/// VL - 116 SP - 855 EP - 867 M3 - 10.1016/S0092-8674(04)00215-6 N1 - 10.1016/S0092-8674(04)00215-6 UR - http://dx.doi.org/10.1016/S0092-8674(04)00215-6 ER - TY - JOUR AU - Sheinerman, F. B. AU - Giraud, E. AU - Laoui, A. TI - High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding JA - J. Mol. Biol. PY - 2005/// VL - 352 SP - 1134 EP - 1156 M3 - 10.1016/j.jmb.2005.07.074 N1 - 10.1016/j.jmb.2005.07.074 UR - http://dx.doi.org/10.1016/j.jmb.2005.07.074 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. TI - The hallmarks of cancer JA - Cell PY - 2000/// VL - 7 SP - 57 EP - 70 M3 - 10.1023/A:1009206113613 N1 - 10.1023/A:1009206113613 UR - http://dx.doi.org/10.1023/A:1009206113613 ER - TY - JOUR AU - Heinrich, M. C. AU - Blanke, C. D. AU - Druker, B. J. AU - Corless, C. L. TI - Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies JA - J. Clin. Oncol. PY - 2002/// VL - 20 SP - 1692 EP - 1703 M3 - 10.1200/JCO.20.6.1692 N1 - 10.1200/JCO.20.6.1692 UR - http://dx.doi.org/10.1200/JCO.20.6.1692 ER - TY - JOUR AU - Shimizu, A. TI - The dermatofibrosarcoma protuberans-associated collagen type I[alpha]1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB JA - Cancer Res. PY - 1999/// VL - 59 SP - 3719 EP - 3723 ER - TY - JOUR AU - Gilliland, D. G. AU - Griffin, J. D. TI - Role of FLT3 in leukemia JA - Curr. Opin. Hematol. PY - 2002/// VL - 9 SP - 274 EP - 281 M3 - 10.1097/00062752-200207000-00003 N1 - 10.1097/00062752-200207000-00003 UR - http://dx.doi.org/10.1097/00062752-200207000-00003 ER - TY - GEN AU - Cherrington, J. M. AU - Strawn, L. M. AU - Shawver, L. K. TI - Advances in Cancer Research PY - 2000/// SP - 1 EP - 38 ER - TY - JOUR AU - Mendel, D. B. TI - In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship JA - Clin. Cancer Res. PY - 2003/// VL - 9 SP - 327 EP - 337 ER - TY - JOUR AU - Motzer, R. J. TI - Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma JA - J. Clin. Oncol. PY - 2006/// VL - 24 SP - 16 EP - 24 M3 - 10.1200/JCO.2005.02.2574 N1 - 10.1200/JCO.2005.02.2574 UR - http://dx.doi.org/10.1200/JCO.2005.02.2574 ER - TY - JOUR AU - Ebos, J. M. TI - A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma JA - Mol. Cancer Res. PY - 2004/// VL - 2 SP - 315 EP - 326 ER - TY - JOUR AU - Lyons, J. F. AU - Wilhelm, S. AU - Hibner, B. AU - Bollag, G. TI - Discovery of a novel Raf kinase inhibitor JA - Endocrine Relat. Cancer PY - 2001/// VL - 8 SP - 219 EP - 225 ER - TY - JOUR AU - Wilhelm, S. AU - Chien, D.-S. TI - BAY 43-9006: preclinical data JA - Curr. Pharm. Design PY - 2002/// VL - 8 SP - 2255 EP - 2257 M3 - 10.2174/1381612023393026 N1 - 10.2174/1381612023393026 UR - http://dx.doi.org/10.2174/1381612023393026 ER - TY - JOUR AU - Wilhelm, S. M. TI - BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis JA - Cancer Res. PY - 2004/// VL - 64 SP - 7099 EP - 7109 M3 - 10.1158/0008-5472.CAN-04-1443 N1 - 10.1158/0008-5472.CAN-04-1443 UR - http://dx.doi.org/10.1158/0008-5472.CAN-04-1443 ER - TY - JOUR AU - Bergers, G. AU - Song, S. AU - Meyer-Morse, N. AU - Bergsland, E. AU - Hanahan, D. TI - Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors JA - J. Clin. Invest. PY - 2003/// VL - 111 SP - 1287 EP - 1295 M3 - 10.1172/JCI200317929 N1 - 10.1172/JCI200317929 UR - http://dx.doi.org/10.1172/JCI200317929 ER - TY - JOUR AU - Yeon, C. H. AU - Pegram, M. D. TI - Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer JA - Invest. New Drugs PY - 2005/// VL - 23 SP - 391 EP - 409 M3 - 10.1007/s10637-005-2899-8 N1 - 10.1007/s10637-005-2899-8 UR - http://dx.doi.org/10.1007/s10637-005-2899-8 ER - TY - JOUR AU - Goldberg, R. M. TI - Cetuximab JA - Nature Rev. Drug Discov. PY - 2005/// IS - suppl. 1 SP - S10 EP - S11 ER - TY - JOUR AU - Kerr, D. G. TI - Targeting angiogenesis in cancer: clinical development of bevacizumab JA - Nature Clin. Pract. Oncol. PY - 2004/// VL - 1 SP - 39 EP - 43 ER - TY - JOUR AU - Cohen, M. H. AU - Williams, G. A. AU - Shridhara, R. AU - Chen, G. AU - Pazdur, R. TI - FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets JA - Oncologist PY - 2003/// VL - 8 SP - 303 EP - 306 M3 - 10.1634/theoncologist.8-4-303 N1 - 10.1634/theoncologist.8-4-303 UR - http://dx.doi.org/10.1634/theoncologist.8-4-303 ER - TY - JOUR AU - Johnson, J. R. TI - Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen JA - Clin. Cancer Res. PY - 2005/// VL - 11 SP - 6414 EP - 6421 M3 - 10.1158/1078-0432.CCR-05-0790 N1 - 10.1158/1078-0432.CCR-05-0790 UR - http://dx.doi.org/10.1158/1078-0432.CCR-05-0790 ER - TY - JOUR AU - Nelson, M. H. AU - Dolder, C. R. TI - Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors JA - Ann. Pharmacother. PY - 2006/// VL - 40 SP - 261 EP - 269 ER - TY - JOUR AU - Fry, D. W. TI - Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts JA - Mol. Cancer Ther. PY - 2004/// VL - 3 SP - 1427 EP - 1438 ER - TY - JOUR AU - Davies, H. TI - Mutations of the BRAF gene in human cancer JA - Nature PY - 2002/// VL - 417 SP - 949 EP - 954 M3 - 10.1038/nature00766 N1 - 10.1038/nature00766 UR - http://dx.doi.org/10.1038/nature00766 ER - TY - JOUR AU - Satyamoorthy, K. TI - Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation JA - Cancer Res. PY - 2003/// VL - 63 SP - 756 EP - 759 ER - TY - JOUR AU - Solit, D. B. TI - BRAF mutation predicts sensitivity to MEK inhibition JA - Nature PY - 2006/// VL - 439 SP - 358 EP - 362 M3 - 10.1038/nature04304 N1 - 10.1038/nature04304 UR - http://dx.doi.org/10.1038/nature04304 ER - TY - JOUR AU - Sebolt-Leopold, J. S. AU - Herrera, R. TI - Targeting the mitogen-activated protein kinase cascade to treat cancer JA - Nature Rev. Cancer PY - 2004/// VL - 4 SP - 937 EP - 947 M3 - 10.1038/nrc1503 N1 - 10.1038/nrc1503 UR - http://dx.doi.org/10.1038/nrc1503 ER - TY - JOUR AU - Wallace, E. M. AU - Lyssikatos, J. P. AU - Yeh, T. AU - Winkler, J. D. AU - Koch, K. TI - Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy JA - Curr. Topics Med. Chem. PY - 2005/// VL - 5 SP - 215 EP - 229 M3 - 10.2174/1568026053507723 N1 - 10.2174/1568026053507723 UR - http://dx.doi.org/10.2174/1568026053507723 ER - TY - JOUR AU - Gorre, M. C. TI - Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification JA - Science PY - 2001/// VL - 293 SP - 876 EP - 880 M3 - 10.1126/science.1062538 N1 - 10.1126/science.1062538 UR - http://dx.doi.org/10.1126/science.1062538 ER - TY - JOUR AU - Tamborini, E. TI - A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient JA - Gastroenterology PY - 2004/// VL - 127 SP - 294 EP - 299 M3 - 10.1053/j.gastro.2004.02.021 N1 - 10.1053/j.gastro.2004.02.021 UR - http://dx.doi.org/10.1053/j.gastro.2004.02.021 ER - TY - JOUR AU - Kobayashi, S. TI - EGFR mutation and resistance of non-small-cell lung cancer to gefitinib JA - N. Engl. J. Med. PY - 2005/// VL - 352 SP - 786 EP - 792 M3 - 10.1056/NEJMoa044238 N1 - 10.1056/NEJMoa044238 UR - http://dx.doi.org/10.1056/NEJMoa044238 ER - TY - JOUR AU - O'Hare, T. AU - Corbin, A. S. AU - Druker, B. J. TI - Targeted CML therapy: controlling drug resistance, seeking cure JA - Curr. Opin. Genet. Dev. PY - 2006/// VL - 16 SP - 92 EP - 99 ER - TY - JOUR AU - Adrian, F. J. TI - Allosteric inhibitors of Bcr-abl-dependent cell proliferation JA - Nature Chem. Biol. PY - 2006/// VL - 2 SP - 95 EP - 102 M3 - 10.1038/nchembio760 N1 - 10.1038/nchembio760 UR - http://dx.doi.org/10.1038/nchembio760 ER - TY - JOUR AU - Wang, Y. TI - A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040 JA - Neoplasia PY - 2005/// VL - 7 SP - 336 EP - 347 M3 - 10.1593/neo.04532 N1 - 10.1593/neo.04532 UR - http://dx.doi.org/10.1593/neo.04532 ER - TY - JOUR AU - Downward, J. TI - Signatures guide drug choice JA - Nature PY - 2006/// VL - 439 SP - 274 EP - 275 M3 - 10.1038/439274a N1 - 10.1038/439274a UR - http://dx.doi.org/10.1038/439274a ER - TY - JOUR AU - She, Q-B. TI - The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells JA - Cancer Cell PY - 2005/// VL - 8 SP - 287 EP - 297 M3 - 10.1016/j.ccr.2005.09.006 N1 - 10.1016/j.ccr.2005.09.006 UR - http://dx.doi.org/10.1016/j.ccr.2005.09.006 ER - TY - JOUR AU - Herbst, R. S. TI - Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer JA - J. Clin. Oncol. PY - 2005/// VL - 23 SP - 2544 EP - 2555 M3 - 10.1200/JCO.2005.02.477 N1 - 10.1200/JCO.2005.02.477 UR - http://dx.doi.org/10.1200/JCO.2005.02.477 ER - TY - JOUR AU - Hainsworth, J. D. TI - Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib JA - J. Clin. Oncol. PY - 2005/// VL - 23 SP - 7889 EP - 7896 M3 - 10.1200/JCO.2005.01.8234 N1 - 10.1200/JCO.2005.01.8234 UR - http://dx.doi.org/10.1200/JCO.2005.01.8234 ER - TY - JOUR AU - Sawyers, C. TI - Targeted cancer therapy JA - Nature PY - 2004/// VL - 432 SP - 294 EP - 297 M3 - 10.1038/nature03095 N1 - 10.1038/nature03095 UR - http://dx.doi.org/10.1038/nature03095 ER - TY - JOUR AU - Canagarajah, B. J. AU - Khokhlatchev, A. AU - Cobb, M. H. AU - Goldsmith, E. J. TI - Activation mechanism of the MAP kinase ERK2 by dual phosphorylation JA - Cell PY - 1997/// VL - 90 SP - 859 EP - 869 M3 - 10.1016/S0092-8674(00)80351-7 N1 - 10.1016/S0092-8674(00)80351-7 UR - http://dx.doi.org/10.1016/S0092-8674(00)80351-7 ER - TY - JOUR AU - Adams, J. A. TI - Activation loop phosphorylation and catalysis in protein kinases: is there functional evidence for the autoinhibitor model? JA - Biochemistry PY - 2003/// VL - 42 SP - 601 EP - 607 M3 - 10.1021/bi020617o N1 - 10.1021/bi020617o UR - http://dx.doi.org/10.1021/bi020617o ER -